Welcome and Introduction to Vi3C

First International Summit on Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Sep

Today In Oncology

Welcome and Introduction to Vi3C

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma

Germline EGFR T790M Associated With Significant Lung Cancer Risk

Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC

Neoadjuvant Anbenitamab/Chemotherapy Combination Improves Response in ERBB2-Positive Breast Cancer

ASCO Breakthrough Studies Target Supportive Care Problems That Can Derail Treatment